CLAIMS

A detailed listing of all claims that are, or were, in the present application, irrespective of whether the claim(s) remains under examination in the application are presented below. The claims are presented in ascending order and each includes one status identifier. Those claims not cancelled or withdrawn but amended by the current amendment utilize the following notations for amendment: 1. deleted matter is shown by strikethrough for six or more characters and double brackets for five or less characters; and 2. added matter is shown by underlining.

1. (Currently Amended) A synthetic, soluble~~, endogenous~~ complex comprising at least one component A and at least one component B, whereby component A is selected from the group of actively binding structures consisting of antibodies, antibody derivatives, antibody fragments synthetic peptides, scFv and component A comprises a binding domain for extracellular surface structures that internalize upon binding of component A of said complex, and component B is a calcium/calmodulin-regulated (CaM) death-promoting kinase that is selected from the group consisting of death-associated protein kinase (DAPk) and death-associated protein kinase 2 (DAPK2) and has a constitutive catalytic kinase activity to affect cell biosynthesis and/or signaling~~, wherein the complex is synthetic, soluble, and endogenous~~.

2. (Cancelled)

3. (Currently Amended) The complex according to claim 1 wherein component A is selected from the group ~~of passively binding structures~~ consisting of ~~allergens, peptidic~~

~~allergens, recombinant allergens,~~ allergen-idiotypical antibodies, ~~autoimmune-provoking structures, tissue-rejection-inducing structures,~~ immunoglobulin constant regions and ~~derivatives, mutants or~~ combinations thereof.

4. (Previously Presented) The complex according to claim 1 wherein the component A is bound to the extra-cellular surface structure.

5. (Previously Presented) The complex according to claim 1, wherein component A comprises two or more of the binding domains.

6-9. (Cancelled)

10. (Previously Presented) The complex according to claim 1, whereby the constitutive kinase activity of component B directly activates or inactivates components of a cell-regulatory pathway through phosphorylation, acetylation, methylation, prenylation, or sulfation, thereby altering the function, gene expression, or viability of a target cell that binds component A.

11. (Previously Presented) The complex according to claim 1, wherein component B comprises DAP-kinase 2 (DAPk2) or a derivative thereof.

12. (Cancelled)

13. (Previously Presented) The complex according to claim 1, comprising

one or more supplementary component S which regulates protein biosynthesis an [[on]] the transcription and/or translation level, and/or enables purification and/or detection of the complex, and/or facilitates translocation of at least component B into the target cell, and/or intracellular separation and/or activation of component B,

wherein the component S is selected from the group of inducible promoters, leader sequences, affinity tags, His tags, translocation domain, amphiphatic sequences and synthetic pro-granzyme B.

14. (Previously Presented) The complex according to claim 1, wherein the components A and B are chemically coupled and/or genetically fused to each other.

15. (Currently Amended) The complex according to claim 1 comprising amino acid sequence SEQ ID NO: 2 or [[,]] SEQ ID NO: 4 ~~or SEQ ID NO: 6~~.

16-20. (Cancelled)

21. (Previously Presented) A medicament comprising the complex of claim 1 disposed in a physiologically acceptable dosage form.

22-24. (Cancelled)

25. (Previously Presented) The complex of claim 1 wherein the constitutive catalytic kinase causes cell death after internalization of the complex into the cell.

26. (Previously Presented) The complex of claim 2 wherein the component A binds to a cluster of differentiation (CD) antigen, cytokine receptor, hormone receptor, growth factor receptor, ion pump, or channel-forming protein.

27-30. (Cancelled)